Institut de Recherches Internationales Servier
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Institut de Recherches Internationales Servier sits in the top decile of US sponsors by registered trial count (#583 of 15,742 sponsors by registered trial count).
Institut de Recherches Internationales Servier: 27 sponsored US clinical trials, 5 recruiting.
Institut de Recherches Internationales Servier sponsors 27 registered US clinical trials on ClinicalTrials.gov, 5 of them currently recruiting, and 11 completed. 6 of these trials are in Phase 3-4 (later-stage) and 21 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Untreated AML, with 3 trials.
Top-decile sponsor footprint
Institut de Recherches Internationales Servier ranks in the top decile of sponsors by registered trial count (#583 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
11 of 15 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (73.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
27 total, page 1 of 1
A First-in-human Study of S230815 in Pediatric Participants With KCNT1-related Developmental and Epileptic Encephalopathy
NCT07227857
Ivosidenib Plus Durvalumab and Gemcitabine/Cisplatin as First-Line Therapy in Participants With Locally Advanced or Metastatic Cholangiocarcinoma With an IDH1 Mutation
NCT06501625
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
NCT06465953
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
NCT05786924
Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation
NCT02074839
Vorasidenib in Combination With Temozolomide (TMZ) in IDH-mutant Glioma
NCT06478212
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
NCT05484622
S095029 as Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Followed by an Expansion Part With Triple Combinations in Patients With Metastatic Gastric or Colorectal Cancers
NCT05162755
A Study to Evaluate the Long-term Safety of Patients With Advanced Lymphoid Leukemia Who Have Been Previously Administered With UCART19
NCT02735083
Study of Vorasidenib (AG-881) in Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 or IDH2 Mutation (INDIGO)
NCT04164901
Study of AG-120 (Ivosidenib) vs. Placebo in Combination With Azacitidine in Participants With Previously Untreated Acute Myeloid Leukemia With an IDH1 Mutation
NCT03173248
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation
NCT02632708
A Study of Vorasidenib in Participants With Moderate or Mild Hepatic Impairment and Matched Participants With Normal Hepatic Function
NCT05674474
Phase 3 Study of Futuximab/Modotuximab in Combination With Trifluridine/Tipiracil Versus Trifluridine/Tipiracil Single Agent in Participants With Previously Treated Metastatic Colorectal Cancer
NCT05223673
Efficacy and Safety of S95011 in Primary Sjögren's Syndrome Patients
NCT04605978
SPARK-ALL: Calaspargase Pegol in Adults With ALL
NCT04817761
Phase I/II Trial of S64315 Plus Azacitidine in Acute Myeloid Leukaemia
NCT04629443
Phase I Dose Escalation Study of Intravenously Administered S64315 in Combination With Orally Administered Venetoclax in Patients With Acute Myeloid Leukaemia.
NCT03672695
Efficacy and Safety of Bumetanide Oral Liquid Formulation in Children Aged From 2 to Less Than 7 Years Old With Autism Spectrum Disorder.
NCT03715153
Study of AG-120 and AG-881 in Subjects With Low Grade Glioma
NCT03343197
Study of AG-270 in Participants With Advanced Solid Tumors or Lymphoma With MTAP Loss
NCT03435250
Phase I Study of S64315 Administred Intravenously in Patients With Acute Myeloid Leukaemia or Myelodysplastic Syndrome
NCT02979366
Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy)
NCT02989857
Dose Escalation Study of UCART19 in Adult Patients With Relapsed / Refractory B-cell Acute Lymphoblastic Leukaemia
NCT02746952
Study of UCART19 in Pediatric Patients With Relapsed/Refractory B Acute Lymphoblastic Leukemia
NCT02808442
Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation
NCT02481154
Study of Orally Administered AG-120 in Subjects With Advanced Solid Tumors, Including Glioma, With an IDH1 Mutation
NCT02073994
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 19 |
| Phase 2 | 2 |
| Phase 3 | 6 |
Therapeutic Areas
What is open in the Institut de Recherches Internationales Servier pipeline
5 recruiting of 27 indexed (19% open); 11 completed (41%).
Phase mix: 6 late (III/IV) vs 21 early (I/II) (early-phase heavy).
Top condition: Untreated AML (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Institut de Recherches Internationales Servier: open-pipeline peers nationwide
Peers matched on 27 registered trials and 19% open enrollment, not the therapeutic-area sidebar.
Institut de Recherches Internationales Servier sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 27 trials (± recruiting share)
- Akron Children's Hospital · 27 trials · 7% recruiting
- ArQule, Inc., a subsidiary of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc. (Rahway, NJ USA) · 27 trials · 0% recruiting
- AVEO Pharmaceuticals · 27 trials · 7% recruiting
- Dompé Farmaceutici S.p.A · 27 trials · 15% recruiting
Sponsors near 19% open enrollment (± trial volume)
- Florida Atlantic University · 19% recruiting · 27 trials
- Natera · 19% recruiting · 27 trials
- Nemours Children's Clinic · 19% recruiting · 108 trials
- Thomas Jefferson University · 18% recruiting · 292 trials
Related
What to do with this Institut de Recherches Internationales Servier page
27 registered trials is a research-attention snapshot, not an endorsement of Institut de Recherches Internationales Servier or any single study.
- 5 of Institut de Recherches Internationales Servier's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Untreated AML is the condition Institut de Recherches Internationales Servier studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Untreated AML trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Institut de Recherches Internationales Servier pipeline card: 27 registered trials from official public datasets.Report a data error.